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Abstract
Metastasis is a multistep process during which tumor cells separate from a primary
tumor, penetrate the bloodstream, evade host defenses, and colonize distant organs.
This final and fatal step in tumor development is the cause of more than 90% of
cancer related deaths. Therapies and diagnostics can be targeted to metastasis at
three points in its progression: the primary tumor, the secondary tumor, and
circulating tumor cells (CTCs). While much work has focused on primary tumors,
less effort has concentrated on targeted isolation, detection and therapy of deeply
penetrated metastases and CTCs. Here, I discuss cell and nanomaterial-based
approaches for detecting and ablating these malignant populations. The number of
CTCs in the blood directly correlates with disease progression; however, the lack of
definitive markers has limited their isolation and characterization. I have
demonstrated the potential use of platelets as a cell-based marker for isolation and
detection of CTCs. Using phage display technology, it was possible to identify
candidate peptides specific to mesenchymal-like tumor cells that may mimic the
motile and aggressive CTC population. In order to detect and ablate metastases and
CTCs, M13 bacteriophage was engineered into a platform for simultaneous tumor
targeting, imaging, and therapy. Single-walled carbon nanotubes (SWNTs) and
doxorubicin, a chemotherapeutic agent, were loaded on phage for fluorescent near-
infrared imaging and cytotoxicity of metastatic lesions, respectively. The near-
infrared optical properties of SWNTs in the "second window" make them promising
candidates for imaging nascent and deeply seeded tumors. This approach provides
an 'all-in-one' platform for targeted fluorescence imaging and efficient drug delivery
and may allow for real-time monitoring of tumor response to drug regimens.
Thesis Supervisor: Angela M. Belcher
Title: Germeshausen Professor of Materials Science and Engineering and Biological
Engineering
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Chapter 1: Isolation of Circulating Tumor Cells (CTCs) with
Non-Epithelial Markers
1.1 Background
1.1.1 Circulating Tumor Cells and Metastasis
Metastasis is a multistep process in which tumor cells separate from a
primary tumor, penetrate the bloodstream and lymph nodes, evade host defenses,
exit circulation and colonize distant organs'. This final and fatal step in tumor
development is responsible for more than 90% of cancer related deaths; as a result,
detecting and characterizing migrating and invasive tumor cells, the precursors of
metastasis, are key obstacles in the battle against cancer 2. Circulating tumor cells
(CTCs), cells that have detached from a primary tumor and circulate in the
bloodstream, may be the seeds of metastasis - CTC levels in peripheral blood are a
predictor of overall survival in patients with metastatic disease. Unfortunately, little
is known about the molecular characteristics of these cells. Two hurdles stand in
the way of CTC characterization. First, since these cells are extremely rare (1 in 109
cells in blood), it is difficult to enrich CTCs from a large background of blood cells.
Second, a lack of non-epithelial markers for CTCs may prohibit the isolation of the
cells most primed for metastasis.
The formation of metastasis is an inefficient process. Nearly 106 tumor cells
per gram of tumor tissue can be introduced into the bloodstream each day3.
Epithelial cells from primary tumor tissue are unequipped to survive in circulation,
as they have a rigid phenotype and are dependant on anoikis. As such, within 5
minutes of entering circulation, over 85% of these cells disappear 4. The circulating
tumor cells (CTCs) that persist may be resistant to anoikis and primed to overcome
the mechanical and immunological stresses of the blood such as the shearing effects
of hemodynamic forces and the cytotoxic activity of natural killer cells'.
Enumeration of CTCs in the peripheral blood of cancer patients has diagnostic
potential: 5 or more CTCs per 7.5ml of blood in patients before first-line
chemotherapy is a better indicator of overall survival than conventional imaging
procedures5 . Beyond enumeration, molecular characterization of CTCs may provide
a non-invasive method to diagnose, treat, and monitor malignancy using blood
samples. CTC based diagnostics have been limited by the ability to isolate and
enrich rare CTC populations from the blood. Further, a lack of proven enrichment
technologies limit genomic and proteomic analysis of CTCs, as leukocyte
contamination distorts molecular analysis of rare cells. As such, the most pressing
problem in CTC research is the purification and enrichment of malignant CTCs.
1.1.2 Circulating Tumor Cells and the Epithelial to Mesenchymal Transition
Previous attempts to purify CTCs have employed flow cytometry6, fibre optic
array scanning7, immunomagnetic beads 8, microfluidic separation 9, and high
throughput optical imaging'0 ' 11. Most of these technologies have relied on an
epithelial marker, epithelial-cell-adhesion-molecule (EpCAM), to distinguish tumor
cells from leukocytes and erythrocytes in the blood. EpCAM is frequently over
expressed in a number of epithelial carcinomas in the lung, breast, prostate, head
and neck, and liver 9. However, while EpCAM has been useful in establishing proof-
of-concept of the diagnostic potential of CTCs, it may not be a comprehensive CTC
marker.
While epithelial cells in a solid tumor may robustly express EpCAM,
disseminated tumor cells in the bloodstream are believed to undergo an epithelial to
mesenchymal transition (EMT) that induces migratory and invasive properties,
upregulates stem cell properties, inhibits apoptosis and senescence, contributes to
immunosuppression, and down regulates epithelial characteristics1 2. The
mesenchymal state is associated with the capacity to metastasize and differentiate
as well as evade chemotherapy". Previous work isolating CTCs yields cells with an
epithelial phenotype reminiscent of the primary tumor13. Gene and protein
expression studies have also relied on such epithelial markers to isolate CTCs14,1s.
However, this approach may fail to screen for highly malignant disseminated cells
with mesenchymal characteristics. Cells that have undergone an EMT and are
poised to seed a secondary tumor may not express EpCAM and would be invisible to
current CTC detection technologies. Thus, a more comprehensive marker for post
EMT CTCs must be used to isolate, enrich, and subsequently characterize cells.
1.2 Cell-based Methods for Circulating Tumor Cell Isolation
1.2.1 Background: Circulating Tumor Cell Interactions with Platelets
In addition to undergoing EMT to survive in the blood, evidence suggests that
CTCs evade the immune response and extravasate from the vasculature by
interacting with cells in the blood' (Figure 2a). The most compelling evidence is
the inhibition of metastasis by depletion of platelets and the restoration of
metastatic potential after platelet repletion in a mouse model' 6 , 17.
Platelet/fibrinogen clots surrounding the tumor cells may shield them from natural
killer cell surveillance. In mice lacking functional natural killer cells, fibrinogen
deficiency was not a determinant of metastatic potential' 8 . Platelets also promote
vascular extravasation of CTCs by releasing vascular endothelial growth factor
(VEGF) and promoting vascular hyperpermeability'. These platelet interactions are
up regulated in the tumor microenvironment. Thrombin, a potent platelet activator,
is up regulated at hypoxic sites such as the tumor. Further, tumor cells activate
platelets by secreting cysteine proteases and ADP19. This interplay between
platelets and tumor cells is vital for successful metastasis and may provide insight
useful in developing new therapeutic strategies to fight metastasis. Recent work has
shown that platelets can induce an EMT in tumor cells via secretion of TGF-p
(Personal Communication, Myriam Labelle - Hynes Lab, MIT). This work may show
that EMT may not be restricted to the primary tumor, and that epithelial-like cells
that enter the blood may undergo an EMT after interacting with platelets.
This comprehensive body of work points to a vital role for platelets in
metastasis. By co-opting platelets, tumor cells are protected from cytotoxic forces
and effectively escorted to a secondary site. While little is known about the
molecular characteristics of CTCs, platelets are well studied. As such, they may
represent a powerful marker in CTC isolation. Here I outline an approach in
enumerating CTCs using platelets as a marker. Using flow cytometry, I isolated
complexes with the surface expression of a platelet but with the size and
complexion of a tumor cell. These platelet tumor cell complexes may be the seeds of
metastasis.
1.2.2 Formation and Characterization of Platelet/Tumor Cell Complexes in
vitro
1.2.2.1 Proof of Concept Studies
In order to investigate platelet/tumor cell complexing, I used flow cytometry
to identify cells that were the size of tumor cells (10-20 microns) but had the
surface expression of platelets. Two platelet markers were used to identify
platelets: CD41 and P-selectin. CD41 (integrin aQib) associates with CD61 (integrin
Pii) to form the gpllb/IlIa (CD41/CD61) complex. This complex is expressed on
platelets, megakaryoctes and early hematopoietic progenitors, and binds to
fibrinogen, fibronectin, vitronectin, von Willebrand factor, and thrombospondin. It
is necessary for platelet adhesion and aggregation 20. Selectins (CD62) are a family
of cell-surface proteins that bind carbohydrates and mediate cellular interactions
with leukocytes. L-selectin is expressed on the majority of B and T lymphocytes and
interacts with carbohydrates on endothelial cells. P-selectin (CD62P) is expressed
on activated platelets and endothelial cells and binds to sialyl-lewis-x (sLex) on
neutrophils and monocytes. Interestingly, aberrant expression of carbohydrates
such as sLex is associated with tumor formation and metastasis 21.
Platelet activation is the culmination of the clotting cascade and can be
induced by a number of molecules and proteins including thrombin and ADP.
Acting through cell surface receptors, ADP activates platelets resulting in shape
change, aggregation, and release of granule contents. ADP also causes a number of
intracellular events including inhibition of adenylyl cyclase, mobilization of calcium
from intracellular stores, and rapid calcium influx in platelets 22, 23. ADP mediated
platelet activation triggers a positive feedback loop, as activated platelets secrete
ADP in order to form a dense clot.
Cell Type Size (microns) Abundance Markers
(Per ml blood)
Circulating tumor 10-30 Unknown Unknown
cell (CTC) -1-100 EpCAM
Erythrocyte 6-8 4.5-6 E6
Platelet 2-4 150-450 E3 CD41, CD62P
Granulocyte 12-15 3-7 E3 GR-1 (Granulocyte
differentiation
antigen 1)
Monocyte 16-20 .22-.55 E3 F4/80, CD11.b
Lymphocyte 8-10 1.45-3.3 E3 CD45
Table 1: Composition of blood by cell type. CTCs make up a miniscule and poorly described portion of
patient blood. A number of markers for specific blood cells were used to identify CTCs using flow
cytometry.
Platelet surface expression was confirmed by flow cytometry (Figure 1).
Washed platelets were prepared from mouse whole blood (detailed in Materials +
Methods). While unstained platelets showed no surface expression (Figure la,c),
platelets stained positive for CD41 (Figure 1b) and CD62P (Figure id). As
expected, platelets activated with ADP showed an up-regulation of P-selectin
(Figure le).
In order to establish proof of concept of platelets as a marker for CTCs,
experiments were carried out on well-characterized mouse tumor cells lines. The
393M1 (liver to lung adenocarcinoma) and Tearly (early stage 393M1) cell lines
were used for these experiments because they represent different stages in tumor
formation. While 393M1 cells are known to be metastatic, Tearly cells are isolated
from an early stage primary liver adenocarcinoma and may not form metastasis
(Personal Communication, Monte Winslow- Jacks Lab, MIT). Ideally, these cell lines
allow for correlation of malignancy with platelet binding. The hypothesis was that
those cells better primed for metastasis (393M1) would bind platelets more
efficiently than earlier stage tumor cells or non-malignant cells (Tearly).
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Figure 1: Confirmation of platelet staining and activation. (A,c) Unstained platelets are compared to
platelets stained with (B) CD41 or (D) P-selectin. Addition of ADP activates platelets and up-regulates P-
selectin expression (E). EpCAM staining represents a negative control, as this epithelial marker is not
expressed on platelets.
In order to recapitulate tumor cell platelet binding in vitro, 393M1 and Tearly
cell lines were trypsinized and mixed with platelet rich plasma (PRP) for an hour at
37 *C (detailed in Materials and Methods). Platelet-tumor cell complexes were then
stained with platelet markers (CD-41, P-selectin), tumor cell markers (Ep-CAM) and
4', 6-diamidino-2-phenylindole (DAPI), a fluorescent dye that has a strong affinity
for DNA. An outline of markers used for different cell types is shown in Table 1.
Platelet-tumor cell complexes were identified by flow cytometry (Figure 2). In the
absence of PRP, tumor cells did not stain for platelet markers CD41 or CD62P. When
PRP was mixed with tumor cells, binding occurred and cells stained positive for
both CD41 and CD62P (Figure 2c,d). Interestingly, cells stained positive for platelet
marker CD62P, which is exclusively expressed on activated platelets. This result
may suggest that tumor cells locally activate platelets by secreting ADP or thrombin.
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Figure 2: Complexing of platelets and tumor cells. (A) Fluorescence microscopy image of platelets bound
to a tumor cell. (B) Unstained 393 tumor cells were mixed with platelet rich plasma and stained for (C)
CD41 or (D) CD62P. The percentage of cells staining for platelet markers is given in the upper right
corner of the plots. Cells were gated on forward scatter, DAPI negative, and GFP positive. The addition
of ADP did not increase platelet-tumor cell complexing (E,F), which may show tumor cell mediated
platelet activation.
To test this hypothesis, platelets were activated by ADP and incubated with tumor
cells (Figure 2e,f). No increase in platelet-tumor cell binding occurred after the
addition of ADP, which suggests that tumor cells are activating platelets and
triggering P-selectin expression. Further, experiments carried out on the Tearly cell
line yielded similar results: Tearly cells complexed with and appeared to locally
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activate platelets. While this data is in vitro, it may indicate that platelet binding is a
universal process rather than one restricted to highly metastatic cell lines. Future
work should be carried out to evaluate the mechanism of tumor-mediated platelet
activation. ELISA or western blot analysis could probe for the amount of thrombin
or ADP in a particular cell type. Further, inhibitors of these molecules could be used
to suppress platelet binding. This work is particularly relevant in the context of
recent work carried out by Myriam Labelle of the Hynes lab at MIT. Labelle has
shown that platelet binding triggers an epithelial to mesenchymal transition in
tumor cells and primes them for metastasis; platelets control EMT by secreting TGF-
p (Personal Communication - Myriam Labelle, Hynes Lab, MIT).
While these initial experiments demonstrate tumor cell-platelet complexing,
the extent of platelet-tumor cell binding was inconsistent. A potential reason for
this inconsistency was the anti-coagulant used in whole blood isolation from mice.
Initial experiments used blood drawn into sodium citrate tubes. Sodium citrate acts
by chelating calcium ions necessary for selectin binding of carbohydrate moieties 24.
Calcium is thus needed for both homotypic interactions between platelets and for
platelet/tumor cell binding. To circumvent this issue, hirudin, an anticoagulant that
acts by inhibiting thrombin rather than chelating calcium, was used 25. Platelet
binding experiments were repeated using hirudin (Figure 3). Interestingly, platelet
binding to tumor cells decreased as compared to experiments done in sodium
citrate (Figure 3c,d and 3b,c). This may be because thrombin is required for
tumor cell mediated platelet activation. Residual hirudin would therefore block
platelet activation and prohibit binding. Alternatively, platelet-tumor cell binding
may be a selectin-independent process and binding could be integrin mediated and
calcium independent.
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Figure 3: Platelet-tumor cell complexing using platelet rich plasma isolated from whole blood in hirudin.
Calcium chelation may alter the dynamics of platelet-tumor cell complex formation. Hirudin, an
anticoagulant that inhibits thrombin, was used to preserve physiological calcium levels. (A) Unstained
393 cells were compared to cells mixed with platelet rich plasma and stained for (B) CD41 or (C) P-
selectin. The use of hirudin did not have a dramatic effect on complex formation.
1.2.2.2 Effect of Shear Flow on Platelet/CTC Complex Formation
In order to better recapitulate in vivo conditions, platelet-tumor cell
suspensions were subjected to a uniform shear field. Hydrodynamic shear induced
collisions augmented platelet-tumor cell binding (Figure 4c,d). A shear rate of
100s-1 dramatically increased platelet binding to tumor cells when judged using
CD41 as a marker. However, this shear force had seemingly no effect when using
CD62P as a marker. This may be because at low shear forces (<100 s-1), platelet
binding is P-selectin-independent/Arg-Gly-Asp (RGD)-dependent. At higher shear
forces (>800 s-1) this process may become P-selectin dependent 26. As such, CD62P
may be up-regulated at higher shear forces because it is a stronger and more
specific interaction than RGD-based binding. In addition to platelet protein
expression, tumor cell protein expression appears to be affected by shear forces
(Figure 4gh), as EpCAM seems be upregulated under flow conditions. Thus,
13
platelet activation and the fluid environment of the vasculature may have an effect
on platelet-tumor cell adhesive interactions, and more work should be done to
examine protein expression changes in response to fluid-mechanical forces.
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Figure 4: The effect of shear flow on platelet and tumor cell protein expression. After applying a shear
force of 100 s-1 to a suspension of platelets and tumor cells, tumor cell forward and side scatter
remained the same (AB). However, platelet expression of CD41 seemed to increase (CD), while platelet
expression of P-selectin remained constant (E,F). It also appears that platelet/tumor cell complexing
increased as a result of shear flow. Finally, tumor cell expression of EpCAM increased as a result of shear
flow (G,H).
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In order to evaluate flow cytometry as a tool for CTC isolation, 393 cells were
spiked into whole blood and recovered via flow cytometry. Since these cells stably
express GFP, their isolation can be confirmed by fluorescence. Tumor cells were
spiked into mouse whole blood and incubated for 1 hr at 37 *C. After erythrocyte
lysis, granulocytes, monocytes and lymphocytes were stained using markers
outlined in Table 1. This counter-staining allowed for facile separation of blood
cells. Using this method, I was able to resolve -10 GFP positive tumor cells per
100,000 WBCs, or 1 tumor cell per 109 total blood cells (-10 ml of total blood).
These initial experiments confirm flow cytometry as a viable method for
enumerating and separating CTCs from peripheral blood.
After proof of concept studies in mice revealed platelet-tumor cell
complexing to be a repeatable in vitro process, we turned to more relevant human
cell lines. Human colonic carcinoma cell lines, LS180 and HT29, were tested for
platelet binding. While LS180 robustly expresses sLex, an antigen for P-selectin on
platelets, HT29 does not express this carbohydrate group (Figure 5). As such, I
expected to see platelet binding to LS180 and negligible binding to HT29.
Unfortunately, this was not the case, as neither cell line appeared to bind human
platelets. Rather than a failure to bind platelets, this result may be an unfortunate
experimental artifact. Antibodies to human isoforms of CD41 and CD62P on
platelets appear to have been compromised during shipping from AbCAM. As a
result, data from these experiments must be reproduced with a fresh batch of
antibodies.
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Figure 5: Sialyl Lewis X staining of H T29 and LS180. (A,B) While HT29 express Sialyl Lewis X, an antigen
for P-selectin on platelets, at basal levels, (c,D) LS180 robustly express this carbohydrate group. (A) and
(C) show unstanined HT29 and LS180, respectively. While (B) and (D) show cells Incubated with an
antibody to CD15s.
1.2.3 Discussion and Future Work
Tumor cells bound by platelets are protected from shear forces and natural
killer cell activity and may have a competitive advantage over other CTCs in seeding
a secondary tumor. With the dearth of definitive CTC markers, platelets are a
promising candidate for further evaluation. Here, I have delineated some early
results investigating the propensity and mechanism of platelet-tumor cell binding in
vitro. From these cursory experiments, it seems that platelets may not bind some
tumor cells better than others - there is no clear correlation between metastatic
potential and platelet binding. Also, tumor cells may locally activate platelets by
secreting ADP or thrombin. Further, the surface expression of both tumor cells and
platelets is altered in response to shear forces, and future work investigating CTCs
should take this change in protein expression into account.
.............. .
Work on a human model of platelet-tumor cell binding has been hampered
by unfortunate complications with reagents. However, this work should be
continued with the goal of identifying differences in platelet-tumor cell binding
under varying shear forces and time courses. In addition, target proteins such as P-
selectin, CD41 and carbohydrate groups such as sLex should be systematically
inhibited in order to investigate the mechanism of complex formation. The final
step of this work in vitro is to use FACS to sort out platelet-tumor cell complexes
from whole blood and re-inject these complexes into mice in order to assay for
metastatic potential. Since platelets protect from natural killer cell activity, it is
imperative that these mice are not immuno-compromised, as the ability of tumor
cells to overcome the immune system appears to be a critical step in metastasis
mediated by platelets.
Once these in vitro experiments have elucidated the mechanism of platelet
binding and its role in metastasis, patient samples should be assayed for platelet-
tumor complexes. Peripheral blood samples from patients with metastatic disease
should be subjected to staining and subsequent flow cytometry. If platelet-tumor
cell complexes exist, they should be isolated and perpetuated in culture. These
complexes should also be injected into mice in order to investigate metastatic
potential. Ideally, there will be a correlation between the number of platelet-tumor
complexes and the severity of a patient's disease state. If this is the case, these
complexes may be the focus of future therapeutic and diagnostic development.
1.3 Phage Based Approaches to Isolate CTCs
1.3.1 Isolation of Mesenchymal like CTCs Using Phage Display
The shift from an epithelial to mesenchymal phenotype is mediated by a
number of transcription factors: Snail, Zeb, E47, KLF8, FoxC2 etc. In particular,
TWIST has been shown to be essential for metastasis and EMT in breast
carcinomas27. The Weinberg group has shown that up regulation of TWIST leads to
degradation of cell-cell adhesion, downregulatioon of epithelial markers
(cytokeratin, E-cadherin), and upregulation of mesenchymal markers (vimentin, N-
cadherin)28. Yang and colleagues went on to create a stable mesenchymal-like cell
line by constitutively up-regulating TWIST in mammary carcinoma cells 28. Using
these two cell lines (TWIST +, TWIST -) as a proxy for mesenchymal-like and
epithelial-like tumor cells, we have used phage display of a library of random
peptide 7-mers fused to minor coat protein pIll of M13 bacteriophage to select for
peptides that bind to mesenchymal-like cells and not to epithelial-like cells (Figure
6).
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Figure 6: Schematic of biopanning approach. A library of ~1010 phage clones was incubated with
mesenchymal-ike (TWIST +) tumor cells, bound and internalized phage was collected and incubated
with epithelial-like (TWIST -) tumor cells. Unbound phage was collected and this sequence was repeated
three times to enrich the phage population. After enrichment, phage clones were sequenced and
mesenchymal binding peptide candidates (MBP) were Identified.
M13 is a filamentous virus that infects bacteria, consisting of five proteins
that encapsulate the viral DNA. It is approximately -1 um in length and 6-7 nm in
diameter. M13 phage is an attractive vector for peptide display since its genotype
relates directly to its phenotype. Consequently, peptides can be genetically
engineered into the multiple coat proteins of the M13 phage for display. Previously,
others have displayed peptides and proteins on the coat proteins with affinity
towards epitopes 29 30, antibodies 31 and mammalian cells for targeting32, 33. Our lab
has engineered a phage vector for peptide display on two coat proteins, p3 and p8
and we have demonstrated multiple display of the M13 scaffold to grow and
nucleate various inorganic materials 34-42. M13 filamentous bacteriophage is an
excellent biological building block due to its multiple peptide display system,
controllable length, and functionality as a nanoscale scaffold for nanoparticle
organization.
Initial biopaning results (detailed in Materials and Methods) yielded 12
candidate mesenchymal binding peptide (MBP) sequences (Figure 7).
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Figure 7: Biopanning results. 12 candidate sequences for the mesenchymal binding peptide are aligned
above. The 7-mer library is book-ended by two cysteine residues, which form a disulfide bond. The
consensus sequence is proline and serine rich, which is common for peptides that bind surface proteins.
While the library did not collapse to a handful of sequences, there are a number of
conserved motifs between the sequences (Figure 7). The 7-mer sequences are
given by positions 2-8 and are sterically constrained by two cysteine residues. The
consensus sequence is proline and serine rich. Proline is a unique amino acid as its
side chain is cyclized onto the backbone nitrogen. As a result, the confirmation of
proline and the preceding residue are restricted. The PxxP motif is a common motif
in peptides specific for proteins, as the prolines form a continuous hydrophobic
strip around the surface of the helix and allows for ideal hydrogen binding sites43.
As such, these isolated sequences are promising candidates for further investigation.
1.3.2 Discussion and Future Work
Peptides isolated via phage display should be further investigated for binding
to mesenchymal-like cells. The most straightforward experiment to be carried out
is a competitive ELISA in which phage specific for mesenchymal-like cells are
incubated with cells and competed off with free MBP. If this competition is
successful, one can estimate the KD of peptide binding. Once a peptide has been
found using phage display, it can be used to isolate mesenchymal-like CTCs from
peripheral blood.
............. ......
In order to isolate CTCs from peripheral blood, the MBP will be biotinylated
and attached to 50nm streptavidin coated Fe203 superparamagnetic bead, and
magnetically labeled cells will be isolated using magnetic-activated cell sorting
(MACS) 44. MACS employs a steelwool column that is magnetized by placing it in a .6
Tesla magnetic field. The magnetic column acts as a sensitive filter for magnetically
labeled cells and allows for a 5-log-fold enrichment of viable cell populations 44. As
proof of concept of the isolation approach, TWIST expressing mesenchymal-like
cells will be spiked into whole blood to mimic a CTC population, and MBP
functionalized magnetic beads will be added to the solution to label CTCs. After
erythrocyte lysis, leukocytes and tumor cells will be applied to a magnetic column
(Miltenyi Biotec) - magnetically labeled tumor cells will be retained by the column
while leukocytes and plasma proteins will be discarded. Cells can be eluted from
the column by removing the external magnetic field or by competing with free MBP.
Several rounds of purification can be carried out in order to enrich tumor cells. If
necessary, negative selection can be carried out by labeling Cd45+ leukocytes with
biotinylated antibodies and running the sample through a streptavidin
functionalized affinity column. This iterative approach allows for control of the
purity of isolated CTCs. By closely monitoring the number of cells spiked into blood
and the number of cells successfully isolated, the efficiency and resolution of this
approach can be quantified. Unfortunately, this approach comes with a number of
limitations. Functionalization of beads to the MBP may alter the specificity of the
peptide. As such, if MACS fails to isolate tumor cells, conjugating MBP to a smaller
bead with a different shape may allow for better purification. Additionally, this
approach is limited by the number of MBP ligands on the surface of the tumor cells.
If these ligands are of low-abundance, cells will have few magnetic nanoparticle
bound and a low magnetic moment, which may prohibit their isolation using MACS
and may require the use of an expensive multi-tesla magnet. While the MBP may
show affinity for mesenchymal-like cells in vitro, this affinity may not translate well
into clinical samples. Since CTCs in the blood are likely more heterogeneous than a
cell line, the MBP may only isolate a subset of CTCs. In addition, this subset may not
represent a particularly malignant group of cells. A number of modifications can be
made to the phage display protocol to direct the selectivity of the MBP. Increasing
the number of alternating rounds of negative and positive selection during
biopanning can increase its specificity. By negatively selecting against leukocytes in
addition to epithelial-like cells, a MBP can be identified that does not bind to blood
cells. In order to better recapitulate in vivo conditions, selection can be carried out
against detached cells in media rather than cells adherent to a plate, as gene
expression may change dramatically in circulation 45 .
In order to generate global gene expression profiles, RNA will be extracted
from isolated mesenchymal-like cells and applied to the Affymetrix Genechip
Human Genome U133 Plus 2.0 Array, which allows for analysis of over 47,000
transcripts 46. To benchmark expression, results will be compared to profiles from
epithelial-like cells. In order to confirm that the isolation procedure has no effect on
gene expression, expression signatures from mesenchymal-like cells isolated from
blood will be compared to signatures from mesenchymal-like cells isolated directly
from culture. If there is a dramatic difference in gene expression attributable to the
isolation procedure, a different procedure may be implemented. For example, the
MBP could be functionalized to microposts in a microfluidic device. While
leukocytes will flow through the device, mesenchymal-like CTCs will be captured.
These cells can then be eluted from the posts by competition with free MBP. This
MEMS device is beneficial in that physiological flow conditions may preserve the
viability of CTCs; however, it is limited by its low throughput, as only small volumes
of blood can be run through each chip at a time. Conversely, a change in gene
expression of mesenchymal-like cells after incubation in blood could be due to
interactions with blood cells (personal communication, Myriam Labelle - Hynes Lab,
MIT). To test this hypothesis, cells in culture could be incubated with whole blood.
After washing the cells to remove unbound blood cells, gene expression analysis
would be carried out.
After these proof of concept studies have confirmed that MACS is a feasible
CTC enrichment strategy that does not alter gene expression, this approach can be.
used to characterize CTCs from patients with varying stages of metastatic disease.
In collaboration with surgeons, blood and primary tumor samples will be collected
from patients that have undergone surgery to excise primary epithelial tumors.
Since the cell lines from previous experiments are mammary carcinoma based, we
will initially try to obtain clinical samples from patients with advanced breast
cancer. Magnetic beads conjugated to the MBP will be used to purify CTCs from the
blood samples. Since CTCs are so rare, multiple rounds of isolation will be carried
out to ensure minimal leukocyte contamination. Since an iterative isolation
procedure may be harmful to cells, we will have to empirically determine how many
rounds of isolation are appropriate. Gene expression of isolated CTCs will be
compared to expression from primary tumor cells from the same patient and to the
TWIST inducible mesenchymal-like and epithelial-like cell line from the Weinberg
group. When comparing patient CTC and patient tumor gene signatures, we will
look for genes that are significantly up/down regulated when cells enter the
bloodstream. We would expect to see up-regulation of mesenchymal markers and
down regulation of epithelial markers as confirmation of an EMT. Further, we can
correlate gene expression of CTCs with clinical characterization of the patient's
disease stage. Cancer can be staged from 0 (carcinoma in situ), to stage IV (evidence
of metastasis) 47. Using principal component analysis (PCA), we may be able to
correlate CTC gene expression with that of primary tumor cells and tumor grade.
PCA may be useful in identifying a handful of candidate genes that are responsible
for survival in the blood and metastatic potential. Future work would be carried out
by examining protein expression levels of these candidate genes, as there tends to
be no correlation between gene and protein expression levels 4 8. While the utility of
gene expression data is limited, it may prove beneficial by yielding a small number
of candidate genes for further characterization 49. In addition to gene and protein
expression analysis, a simpler correlation between CTC number and malignancy will
be studied. Large numbers of circulating epithelial cells in peripheral blood
translate into poor clinical outcomes. By isolating mesenchymal-like rather than
epithelial-like tumor cells from the blood, we may be able to classify malignancy
more accurately and precisely, as mesenchymal-like cells, rather than epithelial-like
cells, may be the precursors of metastasis.
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The paucity of CTCs isolated using MACS may prohibit gene expression
analysis. Ten nanograms of total RNA from CTC and primary tumor samples is
needed to prepare biotinylated hybridization targets with the Affymetrix small
sample target labeling assay5 o; this system is designed to reproducibly amplify 10-
100ng of total RNA using T7 RNA polymerase. Assuming that each cell has
approximately 30pg of total RNA and 2% of total RNA is mRNA51, about 330 tumor
cells are needed in order to get reproducible gene expression results. If a typical
blood draw is 5ml, CTC counts would have to be >60/ml in order to carry out such
genetic analysis. As such, microarray analysis will only be possible if MACS can
reproducibly enrich a large CTC population or if analysis is restricted to patients
with high CTC counts.
An emerging alternative to microarray analysis that is well suited to rare and
heterogeneous CTCs is single-cell quantitative PCR with reverse transcription (qRT-
PCR) (Fluidigm Biomark system). This approach is advantageous in that it can
distinguish between pooled and single cell expression, a short coming of the
microarray approach52, 53. Single cell resolution will be important to find
subpopulations of malignant CTCs and to understand how a single CTC can give rise
to a tumor 4. The drawback of this approach is that it will not yield a global gene
expression profile. Instead, we can examine the expression of a group of query
genes. These genes would include EMT hallmark genes as well as housekeeping
genes such as Actb (beta-actin) and Hprtl (hypoxanthine guanine phosphoribosyl
transferase 1 in order to normalize and benchmark analysis.
1.4 Materials and Methods
Blood Collection
Blood was obtained from Research Blood Components (human blood) or
Bioreclamation LLC (mouse blood). Blood was typically drawn into sodium citrate
tubes. In order to avoid calcium chelation, blood was drawn into hirudin tubes
(Diapharma). Mouse blood was shipped overnight on dry ice, while human blood
was shipped day of on dry ice. Blood was always used within two days of receipt.
Platelet Preparation
Whole blood was centrifuged at 800g for 7 minutes in a tabletop centrifuge. Platelet
rich plasma (PRP) was collected and the remaining blood cells were again
centrifuged for 7 minutes at 800g. The platelet poor plasma was collected and
mixed with the PRP to obtain the desired platelet concentration.
Erythrocyte Lysis
1ml of whole blood is centrifuged for 7 minutes at 800g. Remove the PRP and
resuspend remaining cells in 1.5ml ACK buffer (.15M NH4 Cl, 10mM KHCO 3, .1mM
EDTA). Allow cells to incubate with buffer for 10 minutes. Centrifuge for 3 minutes
at 3000RPM and discard supernatant. Some red blood cells will remain. Resuspend
cells in ACK, incubate and centrifuge. Discard supernatant. A small white pellet
should be visible (white blood cells) - resuspend in PBS to desired concentration.
Cell Lines and Culture
393 and Tearly cell lines were a gift from the Jacks Lab (MIT). HT29 and LS180 were
a gift of the Hynes lab (MIT). All cells were grown in Dulbecco's Minimum Essential
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan,
UT) and 1% penicillin/streptomycin (Invitrogen, CA) at 37 *C in 5% CO2.
Freezing Cells
Cells were preserved by freezing at -80 *C. A confluent 225 cm 2 culture plate was
trpysinized and cells were resuspended in 10% DMSO, 90% FBS. Cells were frozen
in isoproponal containers to control cooling.
Cell Counting
Cells were quantified and their viability assessed using a Vi-Cell Series Cell Viability
Analyzer (Beckman Coulter). This machine was used with permission from the
Lauffenberger Lab (MIT). While this machine was useful in quantifying mammalian
tumor cells, both human and murine platelets were too small to be reproducibly
counted by this machine. Instead, these cells were counted using a hemacytometer.
Formation of Platelet Tumor Complexes
Platelet rich plasma (PRP) or washed platelets are prepared and incubated with
tumor cells for 1 hour at 37 *C on a rocker. Typically 106 tumor cells were mixed
with 108 platelets in PBS in a volume less than 1ml. After incubation, complexes
were separated by centrifuging at 1200 RPM for 5 minutes at room temperature ( a
small red ring is visible around the tumor cells at this step). If using 106 tumor cells,
a pellet should be clearly visible. The supernatant was discarded and the complex
was stained for platelet markers using antibodies on ice (see above). Some
experiments included 10uM ADP during the incubation step (1 hour) for platelet
activation. To form complexes with cells in whole blood, 106 tumor cells were
added to a flow tube and centrifuged at 1200 RPM for 5 minutes. .5 ml of whole
blood was added directly to the cells and lightly vortexed. This solution was
incubated for 1 hour at 37 *C and then centrifuged at 1500 RPM for 7 minutes. The
PRP and the buffy coat were carefully collected such that there was no erythrocyte
contamination. These cells were then stained and run on FACS. White blood cells
were counterstained with biotinylated CD45, GR-1, CD11b and F4180 incubated
with streptavidin-PE-Cy7 beads. In order to recapitulate shear forces, the
vasculature was mimicked by a simple pump apparatus. A Pump33 (Harvard
Apparatus) was connected to plastic tubing (diameter = .5mm, length 500 cm). A
shear force of 100s' was applied using a flow rate of 1.3 ul/s on the Harvard pump.
PRP and tumor cells were mixed and immediately applied to the pump for about 10
minutes.
Antibody Staining
100,000 - 1,000,000 cells were incubated in 100 ul volumes of PBS. Primary
antibodies were added at 1:100 dilutions and secondary antibodies were generally
added at 1:500 concentrations (see lab notebook for precise concentrations for
specific experiments). Cells were incubated with antibodies on ice and protected
from light for 30 minutes to 1 hour. After incubation with either primary or
secondary antibodies, cells were washed 1-3x with PBS by centrifugation at 1200
RPM. In addition to surface markers, cells were incubated with DAPI immediately
before analysis in order to test for cell viability
Antibody List
1. P-selectin (Psel.KO.2.7) (Santa Cruz Biotech, Inc sc-101336) (Mouse anti-
human)
2. PE Goat Anti-Mouse Ig (BD Pharmingen 550589)
3. PE Goat Anti-Rat Ig (BD Pharmingen 550767)
4. Purified Rat IgG1, k Isotype Control (BD Pharmingen 553922)
5. Mouse Monoclonal (104-2) to CD45.2 PE/Cy7 (abcam 25463)
6. Ep-CAM (G8.8) (Santa Cruz Biotech, Inc sc-53532)
7. Rat Anti-mouse CD41 MWreg30 (BD Pharmingen 553847)
8. Mouse Mab CD41 (reacts with human samples) alpha-2b [sz.22] FITC (abcam
19687)
9. Mouse Mab CD62P (reacts with human samples) (AK-6) (ab 33279)
Flow Cytometry
Flow cytometry was carried out on both LSRII and FACScan cytometers. High
throughput automated cytometry was carried out using the LSRII.
Flow Cytometry Data Analysis
Platelet tumor complexes were selected on the following criteria. Side and forward
scatter were characteristic of the tumor cell line. If using the 393 cell line, cells were
GFP positive. Cells stained positive for platelet markers CD41 or CD62P. Cells were
DAPI negative, indicating viability. Cells were CD45, GR-1, CD11b and F4180
negative, indicating that they were not blood cells.
Panning
Panning was conducted with three rounds of positive selection and three rounds of
negative selection. The rounds were conducted in the following order: positive,
negative, negative, negative, positive, positive. Positive selection was carried out
against 393 cells (Jacks Lab) while negative selection was carried out against whole
blood. Phage was amplified and titered between rounds of positive selection.
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Positive Selection
1. Grow epithelial-like cells such that they are over-confluent
2. Prepare phage cocktail/solution: Mix 2E11 pfu in 1 mL 1x PBS with 1% BSA
and protease cocktail
3. Incubate with 3ml serum-free media for 2 h, 37 "C. This is to allow for
'clearing' of the receptors (and possibly the glycocalyx).
4. After serum-free incubation, aspirate media and add 2E11 pfu/mL phage to
(target) cells.
5. Incubate phage 1 h at 37 *AC with gentle rocking to allow time for phage to
be internalized.
6. After incubation, remove supernatant (contains unbound phage) by
aspiration
7. To remove nonspecific binding phage, the cells are washed five times with 3
ml PBS supplemented with 1% BSA and 0.05% Tween-20 at room
temperature in a flow tube
8. After washing add 1 ml of glycine (pH= 2.2, added by HCl) and incubate 8
mm.
9. Remove the supernatant, repeat the wash with glycine, and collect the
supernatant, transferring it into a microcentrifuge tube.
10. Add 150 uL Tris (pH -9.1) to the solution in the micro-centrifuge tube, the
ACID eluted fraction. This collects weakly bound phage to the cells. Save this
fraction.
11. Recover the internalized phage by lysing the cells with 1 ml of 0.1%
triethanolamine (Sigma) in PBS (pH 7.6) for 5 min at RT
12. Neutralize the internalized phage pool with 100 pl of 0.5 M Tris-HCl (pH 7)
13. Vortex and incubate for 30 min on ice.
14. Spin down the cell lysate and collect the supernatant (-1 mL). This is the
CELL fraction. This fraction should have phage that showed affinity towards
target cell.
15. Save 10% CELL fraction for titering. Use the rest of fraction for phage
amplification.
Negative Selection:
1. Clear mesenchymal cells
2. Take 1E11 pfu of amplified phage from previous round and make phage
cocktail in 1 mL sterile PBS with protease inhibitor.
3. Incubate cells with phage cocktail for 1 h, 37 C.
4. Take the supernatant. This fraction will contain unbound phage that did not
bind the mesenchymal-like cells and will be used for panning against
metastatic liver cells.
5. GO TO Panning protocol.
Chapter 2: M13 Bacteriophage as a Platform for Targeted,
Simultaneous Near-infrared Imaging and Efficient Chemotherapy
of Prostate Cancer Cells
2.1 Background: Nanomaterial-Based Therapeutics
Most systematic therapeutic approaches to cancer lack specificity and are not
precisely controlled after injection. The ability to control the functionality and
valency of nanomaterials allows for manipulation of pharmacokinetics and
dynamics and can improve safety, potency, and efficacy over traditional tumor
therapies and imaging techniques. Further, the size and shape of many
nanomaterials yield a large surface area to volume ratio and allow for the
containment and functionalization of an array of targeting, therapeutic or imaging
modalities.
A number of nanomaterials have shown promise in a clinical setting55-5 9 and
many more candidate chemotherapy and imaging agents have been successful in
murine trials. For example, iron oxide and gadolinium (III) nanoparticles can be
functionalized to targeting moities in order to increase the relaxivity of water
molecules in a tumor and subsequently enhance magnetic resonance images, which
may allow for more precise imaging of tumors60, 61. Gold nanorods have been
effective agents of thermolysis by acting as antennas to absorb infrared radiation
and cause tumor cell necrosis62, 63. Single-walled carbon nanotubes (SWNTs),
rolled-up tubes of graphene sheets, have also been recently studied for therapy 64,65,
imaging66-68 and as fluorescent biosensors for nitric oxide 69 and reactive oxygen
species 70. Their quasi-one-dimensional architecture yields a large surface area for
functionalization and drug loading. Further, SWNTs are an attractive candidate for
biomedical imaging because of their high absorption of near infrared (NIR) light,
cross-section of Raman scattering, and NIR band-gap fluorescence ranging from 900
- 1600 nm. NIR fluorophores with emission in the "second window" (900 - 1400
nm) may have greater tissue penetration than those in the first spectral window
(650-900 nm) 71. These probes are advantageous because of the low characteristic
autofluorescence of biological species in the second window, which results in a
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signal to noise ratio that may be 100 fold higher than that in the first window and
may allow for precise and sensitive detection of nascent tumors.
Previous research has established SWNTs as viable imaging and therapeutic
vectors. Several groups have shown SWNT mediated therapeutic delivery or NIR
fluorescence imaging of tumors72. Despite the recent success in utilizing SWNTs for
imaging and therapy, it remains challenging to engineer multifunctional,
biocompatible, and singly-dispersed SWNT complexes that retain fluorescence.
Further, no single platform has demonstrated simultaneous fluorescent second
window imaging and drug delivery, as therapeutic loading may limit the stability of
non-covalently functionalized SWNTs.
The next generation of nanomedicines will have encoded multifunctionality
that allows for targeted and simultaneous therapy and diagnosis (so called
"theranostics"). While a number of nanomedicines used in the clinic target tumors
using the enhanced permeability and retention effect (EPR), targeting to specific
tumor markers may improve the efficacy and safety profiles of nanomaterials by
reducing nonspecific cell uptake. In addition, the ability to simultaneously image
and ablate a tumor will allow for real-time monitoring of the efficacy of a drug
regimen.
M13 is a promising platform for nano-scale therapeutic and diagnostic
delivery because of its genetic tunability and physical characteristics. M13 has been
previously used in biomedical applications for epitope discovery 73, 74, gene
delivery 7s, antibody delivery 76, and in vitro and in vivo ligand discovery 77-79. M13
bacteriophage has five genetically modifiable proteins (proteins p3, p6, p7, p8, and
p9). Expression of material-specific peptides or targeting motifs on various coat
proteins allows for genetic control and tunability of its function 40; the malleability of
the phage genome allows for directed evolution of phage proteins for biomedical
applications. In addition, the highly ordered structure of the 2700 copies of the
major coat protein, p8, and the filamentous shape of M13 (-6.5 nm in diameter and
-880 nm in length) enables the phage to multivalently and cooperatively interact
with one-dimensional nanomaterials such as SWNTs, and the abundance of
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genetically modifiable proteins on the coat of the phage allow for encoding of
multifunctionality.
Particle shape can greatly impact the cellular and tissue interactions of
nanomaterials. Particles with a high aspect ratio (length to width ratio) have been
shown to evade phagocytosis and can only be engulfed when cells interact with the
particle ends80. Investigators have shown that filamentous particles have
circulation times about 10-fold longer than spherical particles 81. Further, surface
charge or zeta potential (electric potential at the hydrodynamic slipping plane of a
particle) is an important factor influencing the behavior of nanomaterials. Particles
with a negative or neutral surface charge avoid non-specific cellular uptake better
than particles with a positive charge8 2. As such, the filamentous shape of M13 may
help inhibit phagocytosis and also enhance circulation half-life in vivo, while the
slightly negative zeta potential of the phage may reduce its nonspecific cellular
uptake.
In the following section, I outline an M13 bacteriphage-based platform for
manipulating single-walled carbon nanotubes (SWNTs) in biological solutions for
multimodal near-infrared (NIR) fluorescent cell-specific imaging and therapy.
SWNTs are stably dispersed by major coat proteins of the M13 bacteriophage
through molecular recognition and retain band-gap fluorescence in the 900 - 1350
nm wavelength range, which may allow for deep tissue imaging. Minor coat protein
p3, located at the proximal tip of M13, was genetically engineered to specifically
target SPARC matricellular protein, a marker overexpressed on metastatic breast
and prostate tumors. The targeted virus-SWNT complex serves as a NIR imaging
agent and allowed for sensitive and selective NIR imaging of cells with varying
expression levels of SPARC. Controlling M13-SWNT stoichiometry allowed further
functionalization of the viral major coat with a chemotherapeutic agent for targeted
drug delivery in vitro. Doxorubicin (DOX) delivered by the M13-SWNT complex
inhibited cell growth 400x more efficiently than free DOX, and was restricted to
SPARC expressing cells. This approach provides an 'all-in-one' platform for targeted
NIR fluorescence imaging and efficient drug delivery.
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Figure 8:A schematic of the M13 virus-based platform. (Figure components not to scale) (A) M13-SBP-
SWNT-DOX complex. The filamentous shape of M13 bacteriophage and high aspect ratio allow for
favorable physical interactions In vivo. p3 protein is engineered for targeting SPARC (SSPTGIN) and p8
protein is modified for SWNT binding and drug conjugation (DVYESALP). The secondary structure of a
single p8 protein Is shown inset and an inserted 8-mer peptide sequence is displayed on the amino-
terminus of the p8 protein. The tyrosine residue In red is hypothesized to interact with hydrophobic
SWNTs while the free carboxylate group on aspartic acid is used for drug conjugation. . Doxorubicin is
depicted with a blue sphere. (B) A helical structure of 2,700 copies of p8 protein along the M13 virus
with five-fold rotational and two-fold screw symmetry, allowing for multivalent and cooperative binding
of SWNTs. Rendering was based on a structural model of M13 virus, 2COW.pdb. (software: Swiss-PDB)
(Courtesy of Hyunjung Yi)
2.2 Theranostic Properties of M13 Bacteriophage and Single-Walled Carbon
Nanotubes (SWNTs)
2.2.1 Creation of M13-SWNT Complex (Hyunjung Yi)
To bind and disperse SWNTs non-covalently along the length of virus
wrapped by p8 major coat proteins, 8mer peptide sequences displayed on p8 that
show binding affinity towards SWNTs were identified through biopanning (see
Materials and Methods). After several rounds of iterative panning against SWNT
film, consensus sequences were identified. The three most frequently appearing
clones, DPSRLANE, DKSIEPLP, and DVYESALP (designated p8cs#1, p8cs#2, p8cs#3
respectively), were investigated for binding and dispersion of SWNTs. Well-
dispersed HiPco (high-pressure CO decomposition) SWNTs in water with 2wt%
sodium-cholate were dialyzed extensively against surfactant-free buffer in the
presence of each virus clone83. SWNT solution without virus was also dialyzed as a
negative control. After dialysis, only p8cs#3 formed a homogeneous solution with
SWNTs whereas other clones and negative control formed black aggregates (Figure
9). This solubility suggests that p8cs#3 had a binding affinity strong enough to
disperse SWNTs in aqueous solution. Interestingly, only p8cs#3 had an aromatic
residue, tyrosine (Y), which is thought to preferentially interact with the graphene
sidewall of carbon nanotubes (Figure 8a) 84,85.
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Figure 9: Binding test results. (A) Each clone was incubated with sodium cholate-dispersed HipCo SWNT
in water and dialyzed against tris-buffered saline (TBS, Tris-HCI 100 mM, NaCI 150 mM, pH. 7.5) for
three days with frequent buffer exchanges. The upper column has the highest virus concentration and
each virus clone has duplicate samples. Only clone p8cs#3 shows homogeneous solutions while others
form black aggregates. (B) SWNT dialyzed with and without virus clone p8cs#3. After 24 hr, black
aggregates are clearly observed for SWNTs dialyzed without virus. (Courtesy of Hyunjung Yi)
To further probe the binding mechanism of p8cs#3 to SWNTs, the
hydrophobicity of the peptide sequence was calculated and plotted (Figure 10a)86.
The peptide insert of p8cs#3 has a hydrophobic moiety sandwiched within a
hydrophilic region and this moiety is believed to interact with SWNTs. Meanwhile,
p8cs#1 lacked a hydrophobic region and p8cs#2 showed lower hydrophobicity than
p8cs#3. In general, t- stacking and hydrophobic interactions are considered the
primary interaction mechanisms between biological molecules and SWNTs 84, 85.
Therefore, it is reasonable to conclude that the combination of iT-n stacking and the
hydrophobic properties of the p8cs#3 sequence are the driving force of the M13-
SWNT binding. While the hydrophobic moiety is small, the overall interaction
between SWNT and the virus is amplified by multivalent binding, as each M13 virus
has 2,700 copies of p8 major coat protein that form well ordered structures with
five-fold-symmetry and two-fold screw symmetry about the major axis (Figure 8b).
Based on the crystallographic data of wild-type M13 virus (PDB ID: 2COW), there
are about 31 p8 peptides in series per 100 nm along the virus. This multivalent and
cooperative binding scheme makes detachment of SWNT off the virus unlikely and
energetically unfavorable.
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Figure 10: SWNT binding and M13-SWNT complex. (A) Hydrophobicity plot of p8 peptide sequences of
various virus clones. Hydrophobicity Is calculated based on the Hopp-Woods scale. Window size is 5. (B)
Proposed scheme of M13(p8cs#3)-SWNT complex. SWNT Is bound along the groove of virus major coat
proteins and the Interaction Is amplified by multivalent and cooperative binding. An arrow indicates an
amino-terminus of a p8 protein. Rendering was based on 2C0W.pdb (software: mercury). (C) HRTEM
Images of SWNT bound along the M13 bacteriophage (outlined in red). Part of the phage major coat was
burned off to clearly show SWNT bound along the virus. Arrows Indicate a single SWNT. (Courtesy of
Hyunjung YI)
A proposed binding scheme for the M13 virus-SWNT is illustrated in Figure
10b. The assembled structure of p8 proteins has ten grooves of ~ 2.5 nm in width
along the phage at the amino terminus of p8 proteins. Since the SWNT-binding
peptides are expressed on the amino terminus of p8, SWNTs can interact with the
SWNT-binding peptides along the grooves. In addition, because SWNT-binding
peptides are inserted on the amino-terminus of p8 protein of wild-type M13, the
amino-terminal peptides of p8cs#3 are longer and more flexible than wild-type
M13. These longer and flexible amino terminal peptides can moderately reorganize
to maximize the ir-u stacking and hydrophobic interactions between the SWNT-
binding peptides and SWNTs while minimizing the surface exposure of hydrophobic
SWNT surface. High-resolution transmission electron microscopy (HRTEM) was
used to visualize the bound SWNT along major coat of the virus (Figure 10c). Part
of the virus major coat proteins has been intentionally burned off during imaging,
clearly identifying bound SWNT.
Although p8cs#3 phage has a strong binding affinity toward SWNT, the ratio
of SWNT to phage affects the stability of the M13-SWNT complex solution. The
complex was stable when the overall ratio of SWNT to virus was less than 4.
However, when the ratio was increased to 30, the complex solution started to
aggregate and eventually precipitated. A number of explanation can explain this
phenomenon: first, as the ratio of SWNT to phage increases, SWNTs can form small
bundles before they are bound by phage to form a complex. Second, when too many
SWNTs are bound per phage, the hydrophobicity of the phage-SWNT complex
increases and the whole complex can aggregate. Therefore, it is worth emphasizing
that not only the binding affinity but also the overall ratio of SWNT to phage is
critical to get a very stable phage-SWNT complex. In this context, the overall ratio of
SWNT to p8cs#3 M13 phage was set to 1:1 throughout this study. Since the
hydrophobic moiety of the p8 protein is small and approximately only 155 of 2,700
copies of p8 are bound by SWNT in the 1:1-M13-SWNT complex, the vast majority of
the surface of the complex remains hydrophilic. In addition, the native negative
surface charge of M13 contributes to the colloidal stability of M13-SWNT through
electrostatic repulsion. The zeta potential of the complex is -45 mV at pH 7.4
(Figure 11b); colloidal particles with absolute zeta potential above 15 mV are
considered stable (Figure 11a) 8.
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Figure 11: Colloidal stability of M13 phage (p8cs#3)-SWNT complex and its optical properties. (A) Phage
disperse SWNTs in solution, while SWNTs crash out of solution in the absence of phage. (B) Zeta
potential of the phage-SWNT complex. (C) UV-vis-NIR absorption spectra for SWNTs dispersed by 2wt/o
sodium cholate (starting SWNTs) in water and SWNTs dispersed by phage in PBS. (D) PL mapping data
for starting SWNTs dispersed by 2wt/o sodium cholate (top) in water and phage in PBS (bottom). The
dotted lines are guides for red-shifting of peaks. The characteristic peaks of SWNT are preserved both in
the absorption spectra (C), and PL spectra (D), even after formation of M13-SWNT, suggesting SWNTs are
well dispersed and the complex is stable. (Courtesy of Hyunjung Yi)
These combined effects allow M13 to stabilize SWNTs in PBS, culture media,
and serum (Figure 12) and prevent SWNT bundling, obviating the need for
chemical functionalization.
Figure 12: Stability of SWNTs in various solutions. Phage-SWNT complexes are stable for several months
in PBS and for several days in culture media and serum. (Courtesy of Hyunjung Yi)
2.2.2 Near-infrared Imaging of Tumor Cells using M13-SWNT Complex
(Hyunjung Yi and Debadyuti Ghosh)
In order to investigate the optical properties of M13-SWNT, UV-vis-NIR
absorption and PL spectra of the complex were measured and compared to starting
sodium cholate-dispersed SWNTs (Figure 11c,d). The characteristic optical peaks
of SWNTs, coming from van-Hove singularities of electronic band structure of
SWNTs 72 are preserved both in the absorption spectra and PL spectra after
formation of M13-SWNT, suggesting that SWNTs are well dispersed. Peak
broadening and red-shifting are observed in absorbance and fluorescence as
previously reported in other systems where surfactants are replaced by polymers66
or other molecules88. Peak broadening and red-shifting are attributed to a
perturbation of electronic structures of nanotubes induced by increased interaction
of polar water with nanotubes, consistent to the proposed binding scheme where
some of the SWNT surface is exposed to water. The peak shifts for the complex are
similar to those from SWNTs dispersed by porous and grooved macromolecules
such as glucose oxidase83. Therefore, our absorption and PL spectra suggest that
closely packed sodium cholate molecules on SWNTs were successfully displaced by
the phage (Figure 11c,d). Moreover, since the starting SWNT composition consists
of metallic and semiconducting tubes, the clear PL peaks confirm that SWNTs are
.............
well dispersed by phage with minimal bundling (Figure 11d). SWNTs dialyzed
without phage showed no PL from semiconducting tubes due to quenching of
fluorescence by metallic tubes, present in the starting SWNT composition, bundled
with semiconducting tubes 89.
After confirming p3 functionality of the phage in the presence of SWNTs on
p8, we examined the ability of M13-SWNT to target metastatic prostate cancer cells
by incorporating a targeting motif into p3 (Figure 8).
Expression profiling has identified secreted protein, acidic and rich in
cysteine (SPARC) as a biomarker upregulated in various human cancers90 , 91.
SPARC, an anti-adhesive and promigratory matricellular glycoprotein, is up-
regulated in patients with aggressive melanoma, breast, brain, prostate, colon, and
lung cancers 92. In addition, SPARC may facilitate cancer cell invasion and
dissemination and is correlated with poor prognosis, suggesting that it may be an
excellent biomarker for identifying and staging metastatic lesions 92. We
investigated SPARC-specific targeting in metastatic prostate cancer cells using M13-
SWNT as a NIR fluorescent probe. A binding peptide identified against SPARC
(SPPTGIN, designated as SBP) 93 was genetically engineered into the p3 minor coat
protein of M13 (p8cs#3) (Figure 8). The targeted complex, M13-SBP-SWNT, was
incubated with human metastatic prostate cancer cell lines LNCaP, C4-2B (SPARC
positive; C4-2B is LNCaP derived line which metastasizes to the bone) and DU145
(SPARC negative) at physiological conditions and imaged in the NIR second window
(950-1,400 nm) using a two-dimensional InGaAs camera (see Materials and
Methods). C4-2B and LNCaP showed noticeable fluorescence (Figure 13a, bottom
right, and middle), whereas DU145 control did not exhibit any fluorescence (Figure
13a, bottom left). Punctate fluorescence was observed in the cytosol, suggesting
possible vesicular uptake (Figure 13a). To quantify targeting, cells were incubated
with M13-SBP-SWNT and harvested for spectra measurements. The fluorescence
intensity was integrated from 1,120 nm to 1,350 nm and normalized (Figure 13b,
c). C4-2B and LNCaP exhibited eleven and five-fold greater intensities than the
DU145 control, respectively (Figure 13c). Even after considerable incubation, there
is negligible non-specific binding to control DU145 (Figure 13a-c). The imaging and
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spectra suggest M13-SBP-SWNT can actively and discriminately target cells in vitro
at relevant physiological conditions. This selective and sensitive fluorescence probe
illustrates the potential of our phage-based approach for targeting and imaging in
vivo metastases in the NIR regime.
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Figure 13: Second window NIR imaging and analysis. (A) Brightfleld (top) and NIR fluorescence images
(bottom) of M13-SBP-SWNT targeting three prostate cancer cell lines with various expression levels of
SPARC, C4-2B (++ SPARC), LNCaP(+ SPARC) and DU145 (- SPARC). Fluorescence from targeted cancer
cells is clearly shown for both LNCaP and C4-2B while there is no obvious fluorescence signal from
DU145. 20 sm-scale bar applies for all 6 figures. (B) PL spectra from targeting various cancer cells,
normalized to the number of cells. (C) Integrated PL intensity from different cell lines. PL spectra were
integrated from 1,120 nm to 1,350 nm and normalized by the number of cells counted after the PL
measurement. C4-2B and LNCaP have about eleven times and five times stronger intensity than DU145,
respectively. P values for LNCaP and C4-2B compared with DU145 were calculated using student t-test. *
p<0.0001, ** p=0.014. p<0.05 is statistically significant. (Courtesy of Hyunjung Yi)
2.2.3 Targeted and Efficient Cytotoxicity using M13-SWNT Platform
To investigate the chemotherapeutic potential of the M13-SWNT platform,
M13-SBP-SWNT complex was further conjugated with chemotherapeutic agents.
Doxorubicin (DOX) is an athracycline antibiotic and a common chemotherapeutic
agent that acts by inhibiting topoisomerase II activity to produce stable DNA double
strand breaks94. While it has been extensively used in the clinic to treat ovarian,
breast, lung, uterine and cervical cancers, DOX injury to non-target tissues via
induction of oxidative stress often results in limited DOX dosing regimens 95. As
such, efficient and targeted delivery of DOX to neoplastic lesions would lower non-
specific toxicity and increase the clinical utility of DOX. DOXIL, a liposome
encapsulated form of DOX, is used in the clinic to treat ovarian tumors96 . More
recently, Liu et al used pi-pi stacking to load DOX on SWNTs and showed improved
efficacy over DOXIL in SCID mice97 .
To actively deliver DOX to targeted cancer cells with fluorescent SWNTs, DOX
was conjugated onto phage by forming a peptide bond between the free amine
group on the drug and carboxylic acids (aspartic acid (D) and glutamic acid (E)) on
the p8 major coat proteins of M13 (p8cs#3)-SBP using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and Sulfo-NHS (Figure 8) after phage-
SWNT complexation. To confirm DOX loading, the complex was precipitated by
PEG-NaCl. The red color of DOX was used to visually confirm loading on M13-SBP-
SWNT: after centrifugation, the SWNT-DOX pellet had a slightly red coloration while
the SWNT pellet was black (Figure 14).
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Figure 14: Conjugation of DOX onto the M13-SBP-SWNT complex. M13-SBP-SWNT complexes conjugated
with DOX was precipitated using standard PEG/NaCI precipitation method of phage to confirm DOX
loading onto the complex. M13-SBP-SWNT with low DOX loading (left) and high loading (middle). The
black color of low loading complex is due to SWNT and high loading is due to both SWNT and DOX.
(right) Free DOX solution (concentration: 0.1 mg/ml) is orange color and show strong absorption at 490
nm wavelength.
DOX loading was quantified by measuring optical absorption of the complex
at 490 nm (the extinction coefficient of DOX at 490 nm is 23 cm 2/mg) (Figure
15a)98. The quantity of loaded drugs on the M13-SBP-SWNT complex decreased as
the overall ratio of SWNT to phage increased, eliminating the possibility of non-
covalent loading of drug on the SWNT surface. An average of 390-450 DOX
molecules were loaded per phage and DOX loading did not interfere with SPARC
mediated targeting or SWNT fluorescence (Figure 15b). The final complex (M13-
SBP-SWNT-DOX) is stable in PBS, and its cytotoxic potential was not diminished
even after several weeks after complexation. This stable multifunctional phage
construct allows for simultaneous targeted NIR imaging and cytotoxic drug delivery
to tumor cells.
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Figure 15: Doxorubicin conjugation to M13-SWNT complex. (A) UV absorption at 490 nm was used to
quantify doxorubicin loading. (B) PL spectrum from M13-SBP-SWNT and M13-SBP-SWNT-DOX. Drug
conjugation does not quench SWNT fluorescence, permitting simultaneous NIR fluorescence imaging
and drug delivery.
In order to investigate the cytotoxic potential of DOX-SWNT-SPARC-phage,
C42B (++ SPARC) and DU145 (- SPARC) cell lines were incubated with DOX-SWNT-
SPARC-phage for 9 hours at 37 *C. Phage was removed, cells were washed with PBS
and were subsequently grown for 14 hours in media. To evaluate cell viability, an
MTT assay was performed and absorbance was read at 570nm. M13-SBP-SWNT-
DOX drastically inhibited growth of SPARC-expressing C4-2B cells while it had a less
significant effect on SPARC negative DU145 cells (Figure 16c), demonstrating
targeted chemotherapy. In contrast, free DOX inhibited cell growth of both cell lines
(Figure 16). Moreover, M13-SWNT-SBP-DOX was more than 245 times more
efficient at inhibiting C42B cell growth than free DOX (Figure 16a). For C4-2B, the
half maximal inhibitory concentration, ICso, of free DOX was 29.5 pg/ml while that of
M13-SBP-SWNT-DOX was 0.12 pg/ml. For DU145, the ICso for free DOX was 198
ig/ml while that of M13-SBP-SWNT-DOX was 28.9 pg/ml (Figure 16b). M13-SBP-
SWNT did not significantly retard cell growth under the same condition used for the
MTT assay for M13-SBP-SWNT-DOX, highlighting DOX as the mechanism of cell
death rather than phage or SWNT.
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Figure 16: Dose-response curves of M13-SBP-SWNT-DOX for C4-2B and DU145. (C) M13-SBP-SWNT-DOX
inhibits growth of SPARC-expressing C4-2B cells about 35 times more efficiently than for SPARC negative
DU145 cells. (A) Dose-response curves of M13-SBP-SWNT-DOX and free DOX for C4-2B. M13-SBP-SWNT-
DOX is more than 245 times efficient at inhibiting C42B ell growth than free DOX, (B) while this
difference is less pronounced in DU145 cells. ICso values are shown in blue (AB) and black (C).
C4-2B DU145
M13-SBP-SWNT- Free DOX M13-SBP-SWNT- Free DOX
DOX DOX
0.120 pg/mi (0.52 29.5 jg/ml (220 28.9 pg/ml (219 198 pg/mi
pM) IM) 4M) (440 IM)
Table 2: ICso values for M13-SBP-SWNT-DOX and free DOX for C4-2B and DU145.
Time course of the cytotoxicity experiments is an obvious factor in
determining efficacy and specificity of drug action. In order to quantify the impact
of incubation time on cytotoxicity, M13-SBP-SWNT-DOX complex was incubated
with C42B cells for a fixed time (9 hours). Cells were washed with PBS and media
was replenished. Cells were able to proliferate in media for 14, 24, 48 or 72 hours
before the MTT assay was performed (Figure 17). The Szoka group at UCSF has
shown that varying this second incubation time has a dramatic effect on the efficacy
of doxorubicin treatment - as incubation time increases IC5o decreases99 . Rather
than an inverse relationship between IC5o and incubation time, our experiments
yielded a constant IC5o regardless of incubation time, which could signal that the full
cytotoxic potential of DOX is realized in the first 9 hours (Figure 17). Free DOX
(Figure 17a) and M13-SBP-SWNT-DOX (Figure 17b) are shown for various time
points. While the ICso remains constant, the steepness of the curves increases with
along with incubation time. This means that lower doses of drug are less effective
and higher doses of drug are more effective with increasing time. Rather than being
a meaningful result, this outcome could be an experimental artifact. After the initial
incubation with free DOX or M13-SBP-SWNT-DOX, a number of cells begin to
undergo apoptosis. Those cells that survive this initial incubation proliferate
quickly and repopulate the cells in the plate. At lower doses, more cells are left to
repopulate the cell population, while at higher doses, more cells are undergoing
apoptosis, and there are fewer cells to proliferate rapidly and mask the cytotoxic
effects of the drug. The outcome of this experiment is poorly understood, and it may
be more beneficial to vary the initial incubation with phage or free DOX in order to
understand the kinetics of drug action.
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Figure 17: Timecourse of doxorubicin mediated cytotoxicity. Cells were Incubated with (A) free DOX or
(B) M13-SBP-SWNT-DOX for 9 hours. After cells were washed and fresh media was replenished, cells
were allowed to proliferate for 14-72 hours before the MTT assay was performed. Unexpectedly, this
variable timecourse did not alter the lCso of doxorubicin, indicating that the drug takes full effect In the
first 9 hours.
2.2.3.1 Intercellular Proteases as a Mechanism for DOX Release
In order for doxorubicin to take effect, it must be released from the phage.
Researchers have demonstrated that doxorubicin linked to an amino acid via a
peptide bond can maintain its cytotoxic potential 00 . After observing DOX mediated
cytotoxicity using M13, we hypothesized that the drug was cleaved from the phage
via intercellular proteases. For example, the amino-terminus of the genetically
engineered p8 protein may be cleaved by chymotrypsin, a serine protease abundant
in mammalian cells. Chymotrysin is known to selectively cleave the carboxyl-
terminus of aromatic residues and may cleave the tyrosine (Y) residue in the p8cs#3
sequence (Figure 8). In order to test this hypothesis, cytotoxicity was studied in the
presence of serine and cysteine protease inhibitors (Figure 18). C42B cells were
incubated with free DOX (Figure 18a) or M13-SBP-SWNT-DOX (Figure 18b). As
expected, the protease inhibitor had little effect on the ICso of cells incubated with
free DOX (Figure 18a), as there is no need for DOX release. In contrast, cytotoxicity
of cells incubated with M13-SBP-SWNT-DOX and protease inhibitor was greatly
attenuated as compared to phage in the absence of protease inhibitor (Figure 18b).
This result supports the hypothesis that drug is released from the phage
.......... .................................
intercellularly by proteases and that the function of the drug is maintained even if it
is attached to a short peptide.
(a) (b)
120 
-120
100 100 -
4o 40
Ree Dox * -M13-88P-SWW-DOX
20 20s
-+ Pro-ease n 
- Protese Onht
0
10 -S10'S 10 -S10
[DOX) (ughn [DOX) (ughni
Figure 18: Doxorubicin is released from phage by intercellular proteases. C42B cells were incubated
with (A) free DOX or (B) M13-SBP-SWNT-DOX In the presence or absence of protease inhibitor cocktail(Roche) and cell viability was assayed using an MTT assay. While M13-SBP-SWNT-DOX mediated
cytotoxicity was reduced by protease inhibitor, that of free DOX remained constant, indicating that the
protease inhibitor is preventing drug release from phage.
In order to more precisely confirm the mechanism of release, M13-SBP-
SWNT-DOX was digested in vitro with chymotrypsin, and the resultant digested
peptide fragments were analyzed using MALDI-TOF mass spectrometry (Figure
19). Chymotrypsin is a digestive enzyme that preferentially cleaves peptide bonds
on the carboxyl side of tyrosine, tryptophan and phenylalanine (Figure 19a). These
amino acids contain and aromatic ring that fits into the hydrophobic pocket of the
enzyme1 01. Chymotrypsin is prevalent in mammalian cells and chymotrypsin
mediated DOX cleavage is a plausible mechanims for drug release from phage.
Phage was digested with chymotrypsin and the resultant peptides were resolved
using a reverse phase C18 column. M/Z spectra were analyzed by integrating the
signal for each peak over each m/z integer value. As such, the output from m/z 500
to m/z 3000 was condensed to 2500 points before analysis. When conducting data
analysis, only peptides in the periplasmic domain of p8 were considered for
chymotrypsin digestion, as they are available for cleavage on the exterior of the
phage (Figure 19a). A number of peptides expected from chymotrypsin digested
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were identified (Figure 19b), and these results highlight this intercellular protease
as a potential mediator of drug release.
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Figure 19: MALDi-TOF to confirm chymotrypsin mediated DOX cleavage. (A) The full protein sequence
of M13 bacteriophage major coat protein p8 is shown. The protein is translated with a signal sequence,
which is cleaved after translocation. The rest of the sequence is comprised of a periplasmic domain and
a transmembrane domain. Here, I assumed that the chymotrypsin only digested the periplasmic region.
The SWNT binding peptide is shown in blue, and the aspartic acid for DOX conjugation is shown in red.
Chymotrypsin cleavage sites are delineated by vertical lines. (B) MALDI-TOF m/z spectra are shown for
whole phage. Several peptides characteristic of chymotryptic digestion were detected.
2.3 Trifunctional Phage
In order to take full advantage of the utility of M13 bacteriophage, we
engineered a phage with triple functionality: targeting, imaging, and cytotoxicity
(Figure 20). This phage was designed via genetic engineering and was not coupled
to SWNT. Protein p3 has been modified to include the SPARC binding peptide
(SSPTGIN), enabling cell targeting. The genomic copy of the p9 protein has been
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modified to include a pelB leader sequence and a biotin acceptor peptide (BAP).
Streptavidin coated fluorophores can be easily added to p9. Further, protein p8 has
been engineered to include a cathepsin-B cleavable linker sequence for drug release
(DFK). Drug is loaded on the asparagine via EDC chemistry and can be released in
the cell by protease cathepsin-B100.
SPPTGIN GLNDIFEAQKIEWHE
Streptavidin FITC
DFK
Figure 20: Schematic of trifunctional 983 phage. Phage was genetically engineered for triple
functionality. A SPARC binding peptide was cloned into p3 for tumor cell targeting (SSPTGIN). P8 was
modified to include a cathepsin-B cleavable sequence for drug release (DFK). Finally, p9 was modified
with a biotin acceptor peptide (GLNDIFEAQKIEWHE) for conjugation of imaging agents.
Trifunctional phage (983 phage) was biotinylated and streptavidin coated
FITC particles were loaded on p9. Phage was incubated with SPARC + C42B cells or
SPARC - DU145. Cells were analyzed for FITC signal using flow cytometry (Data Not
Shown). The signal is extremely low from these experiments; however, this is to be
expected, as there are only 5 copies of p9 per phage. Despite the low signal, C42B
have a level of FITC staining 4x higher than that of DU145, as expected. There are
simply not enough fluorophores bound to the phage. This experiment should be
repeated with fluorophores with a brighter signal. DOX was loaded on trifunctional
phage using EDC chemistry. Phage was pegylated and centrifuged in order to
demonstrate DOX binding (Figure 21). The phage pellets have a distinct red color,
indicating robust DOX binding.
Figure 21: DOX con jugation to 983 phage. DOX was conjugated to 983 phage via EDC chemistry. Phage
was precipitated by PEG NaCl. Left, free DOX did not precipitate with PEG-NaCl. Middle, wild-type phage
bound DOX, and right, 983 bound DOX precipitated with DOX attached (red color).
DOX release by cathepsin-B was quantified by digesting phage with the
protease. After digestion, phage was precipitated by PEG-NaCl and the supernatant
was assayed for DOX using UV-VIS. DOX concentration was 50% higher in those
samples digested by cathepsin-B. While this result does not yield a definitive
confirmation of DOX release, it does provide a candidate mechanism of release for
further study.
2.4 Discussion and Future Work
The M13-SBP-SWNT-DOX platform allows for simultaneous active targeting,
NIR second window imaging, and chemotherapy in vitro. The M13 scaffold stably
disperses SWNTs without losing their optical properties. The engineered phage
encodes for cell-targeting functionality and is a carrier for drug conjugation and
delivery, obviating the need to conjugate functional moieties directly to SWNTs and
potentially compromise their stability and fluorescence. The phage-based platform
circumvents these potential issues and allows for spatial control of targeting ligands
and drugs with SWNTs. This versatile technology is powerful due to the
interchangeability of its components, permitting study of a wide array of cancers.
Potentially, any identified targeting ligands can be readily exchanged onto p3 for
molecular recognition of various cancers. Additional chemotherapeutic agents
could be added or substituted by chemical coi lugation or molecular recognition for
specific targeted therapy of many disease . Targeted therapy reduces the
therapeutic dose of the drug and may p -event off-target cytotoxic effects
(cardiomyocyte death for DOX).
Further work must be done to characteri )e the mechanism of drug release
from phage. While preliminary experiments haN e shown that this process may be
mediated by intercellular proteases, this hypothesis should be confirmed more
precisely. Phage can be digested in vitro Lv a cocktail of proteases, and drug release
can be quantified by mass spectrometry. In addition, specific proteases can be
knocked down in cells using siRNA and cytotoxicity can be assayed using MTT.
In order to enhance the cvtotoxic effects of this platform, the favorable
optical properties of SWNTs can be used for thermal ablation of tumors. SWNT have
recently been used both in vivo and in vitro to destroy tumors using photothermal
effect 6 3, 65, 102-106. Thermal ablation is particularly useful in treating multidrug
resistant tumor cells that are resistant to common DNA alkylating chemotherapeutic
agents. These chemotherapeutic agents target highly proliferative cells that are
constantly replicating DNA and are vulnerable to bioenergetic catastrophel 07? 108.
However, slower growing cells are less susceptible to these therapies and may
repopulate tumors after incomplete chemotherapy. Thermal ablation functions by
exceeding physical cell tolerances to heat (greater than 55 *C) and elicits a
coagulative necrosis which involves protein denaturation and membrane lysis, in all
cells regardless of phenotype102.
While our phage complex has shown success in vitro, it must be further
characterized in vivo. Experiments conducted on mice with C42B, LnCAP, and
DU145 tumors will hopefully show simultaneous imaging and ablation. Ideally,
tumor shrinkage can be tracked using NIR fluorescence derived from M13-SBP-
SWNT complex. Mice can be imaged immediately before and at several timepoints
after treatment in order to quantify efficacy. Perhaps the most interesting
dimension to this project is the ability of SWNTs to image in the "second window"
with greater tissue penetration depth and minimal background from
autofluorescence. In order to test this capability, tumors will have to be grown,
rather than implanted in a deep tissue such as the prostate or pancreas. In these
experiments, it may be prudent to use a LOX-CRE system (Jacks Lab, MIT) to
spontaneously induce a tumor in the prostate and image it using M13-SBP-SWNT-
DOX.
A number of safety concerns surround the phage-SWNT complex. The safety
of M13 in the clinic was recently shown in a phase I clinical trial to identify patient-
specific ligands. The bacteriophage was non-toxic, had no adverse allergic response,
and elicited 'submaximal' humoral immune response1 09. Further experiments
should be done to understand the immunogenicity of M13 in greater detail in a
mouse model. Repeated doses of phage over a long timecourse should be conducted
in order to understand the clinical potential of M13 for drug delivery and imaging. A
recent study showed that mice administered orally or intraperitoneally with a high
dose of short carbon nanotubes did not show any growth or behavior
abnormalities1 0. The long characteristic half-life of filamentous particles in vivo
coupled 8' with the initial safety profile of M13 in humans' 09 and biocompatible
SWNTs 72 cast this platform as a promising candidate for facile imaging and
detection of metastases and simultaneous monitoring of the efficacy of drug therapy
regimens; this initial work suggests the potential use of M13 in a clinical setting.
2.5 Materials and Methods
P8 phage-display Library Screening: a bio-panning
For the bio-panning experiment, Hipco SWNTs were prepared in a form of thin films on
glass substrates to maximize the direct contact of the virus to SWNT and a constructed p8
phage-display library was used. Ten pl of the library solution with 1010 viruses of 2 x106
different p8 sequences were diluted with 250 pl of Tris-buffered saline (TBS, 100 mM
Tris-HCl, 150 mM NaCl, pH 7.5) with different concentration of Tween 20 (TBS-T,
Tween 20 concentration of 0.1-0.5 v/v%), applied to SWNT-films and incubated for an
hour with gentle rocking. The SWNT-film was rinsed with one milliliter of TBS-T ten
times to wash off unbound phage. Bound phage were eluted by 100 RI of 0.2 M Glycine-
HCl, pH 2.2 and/or mid-log E.coli culture to harvest strongly bound virus not eluted by
acid solution. The eluted phages were amplified and the same procedures were repeated
for further rounds with increasing detergent concentration. After each round of panning,
the numbers of eluted and amplified phage counted as PFU were measured using agar
plates containing X-gal/isopropyl-p-D-1-thiogalactopyranoside (IPTG)/tetracycline to set
the input number of phage for each round the same. Also plaques from each round were
amplified and DNA sequenced. DNA sequencing was done at MIT Biopolymers lab.
Binding affinity test
In the binding test, each virus clone with different concentrations was mixed with
sodium-cholate dispersed SWNTs in water and dialyzed against TBS (100 mM Tris-HCl,
150 mM NaCl, pH 7.5, Tween 0.3 v/v%) using 96-well microdialyzer
(Spectrumlabs.com) for 3 days with frequent buffer exchanges. Sodium-cholate dispersed
SWNTs without any virus clones were also dialyzed as a negative control. After the
dialysis, each solution was harvested and transferred to a new 96-well plate for visual
comparison.
Zeta potential measurement
The concentration of virus solution used was 10' 2 /ml in water with 10 mM NaCl. The
stock solution of virus (- 104/ml) was initially dissolved in 10 mM Tris 15 mM NaCl
before diluting in 10 mM NaCl in ddH20. The solution amount used to generate curve
was 30 ml. The ionic concentration of the solution was as set to 10 mM NaCl for all
samples. The pH was then adjusted using 0.1 M NaOH until the pH was around 10. Zeta
potential measurements were then made at an accumulation time of 15 with 5
measurements per sample at 20 V using DelsaNano (Beckman Coulter). Electrophoretic
mobility was calculated using the Smoluchowski approximation (used for particles larger
than 0.2 pm in 1 mM or great salt solution). pH was then adjusted with 0.1 M HCl, and
zeta potential measurements were made at pH increments of 1 until pH 6-6.5. Then
measurements were made at pH increments of 0.5.
Genetic engineering for M13-SBP
SPARC binding peptide (designated as SBP), SPPTGINGGG9 3 , was used for specific
binding to SPARC. Oligonucleotides, 5'[Phos]-GTA CCT TTC TAT TCT CAC TCT
TCA CCA CCG ACT GGA ATT AAC GGA GGC GGG TC -3' and 5'[Phos]-GGC
CGA CCC GCC TCC GTT AAT TCC AGT CGG TGG TGA AGA GTG AGA ATA
GAA AG-3', purchased from IDT (idtdna.com) were annealed to form a DNA duplex.
The cloning vector was extracted from virus p8cs#3 using standard miniprep kit
(QIAGEN). The extracted vector was digested with Eag I and Acc65 I enzymes and
dephosphorylated and agarose-gel purified. Purified vector and DNA duplex were ligated
using T4 DNA ligase at 16'C overnight and electro-transformed to electro-competent
XL-1 blue cells. Transformed cells were incubated for 1 hr and plated and incubated at 37
'C overnight. Blue plaques were amplified and DNA sequenced to confirm the insertion
of oligonucleotides to express SBP on p3.
Preparation of starting SWNTs
As-produced and non-acid treated HiPco single-walled carbon nanotubes (SWNT),
purchased from Unidyme, was diluted in a 2wt% sodium cholate aqueous solution. The
diluted solution was homogenized for 1 hour, coup-horn sonicated for 10 min at 90%
amplitude and then ultra-centrifugated at 30,000 rpm for 4 h to get individually dispersed
SWNT. SWNT concentration was calculated using the extinction coefficient of HiPco
SWNT at 632 nm, E632 nm=0.036 L/mg-cm. A final concentration of the SWNT solution,
~20-40 pg/ml was used in this study. This protocol produces a singly dispersed SWNTs
with dimension about 1 nm in diameter and - 500 nm in length "
Complexation of M13 with SWNTs
1 ml of p8cs#3 virus solution with a concentration of 1.4 x 1014/ml was mixed with 4 ml
of SWNT with concentration of 40 jig/ml. The solution was dialyzed for three days using
dialysis membrane, MWCO of 12,000-14,000 (SpectraLabs.com). The dialyzing solution
started with water with 10 mM NaCl and 0.64 mM NaOH. After the first three buffer
exchanges, the ionic concentration of the buffer was step-wisely increased from 10 mM
to 150 mM and PBS was used after water with 150 mM NaCl.
PL measurement
PL from SWNT was measured with a home-built near-infrared (NIR) PL microscope. An
inverted microscope was coupled to a Princeton Instruments OMA V ID InGaAs array
detector through a PI Acton SP2500 spectrometer. As excitation sources, a 785 nm laser
and a Xe lamp coupled to a monochromator were used for PL spectra and three-
dimensional profiles, respectively. Detection ranges were 900 nm -1,350 nm. For PL
imaging of targeted cells, nanotubes in the cells were excited by 658 nm laser and imaged
and monitored using inverted microscope w. h a Princeton Instruments OMA V 2D
InGaAs array detector and an AxioCam MRn c nlarge-coupled device (CCD) camera.
HRTEM
For high-resolution transmission electron micrt icopy, JEOL 201OF TEM was used. For
TEM analysis, virus-SWNT solutions were 'ropped on Cu Quanti-foil holy grid
(TedPella), washed with ddH20 several times ii d dried.
Cell lines and culture
DU145 and C4-2B human prostate cancer cL1 lines were provided courtesy of Dr.
Kimberly Kelly (University of Virginia). LNCaP j urnan prostate cancer line was given as
a gift by Dr. Juliana Chan (Massachusetts Institute o" Technology). DU145 was grown in
Dulbecco's Minimum Essential Medium (DMEM) SL plemented with 10% fetal bovine
serum (FBS) (Hyclone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen, CA) at
37 *C in 5% CO2 . C4-2B were grown in T-medium (Invitrogen) with 10% FBS and
penicillin/streptomycin. LNCaP were grown in RPMI medium (without phenol red),
supplemented with 10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, and 1%
HEPES buffer.
PL Imaging in vitro
500,000 DU145, LNCaP, and C4-2B cells were plated on poly-lysine coated 35 mm glass
bottom plates (MatTek Corporation). Cells were incubated with 2 ml of 0.29 pg/mL
M13-SWNT in Dulbecco's phosphate buffer saline (DPBS) with calcium and magnesium
(Hyclone) for 12 h at 37 *C. Cells then were washed three times and resuspended with
DPBS. For imaging, signal were collected for 5 -20 s.
Targeting in vitro using PL spectrometry
1,000,000 DU145, LNCaP and C42B cells were plated on 6-well plates (BD Biosciences)
and incubated with 2 ml of 1.8 ptg/mL M13-SWNT solution. Samples were washed three
times with DPBS and harvested with trypsin (Hyclone). Cells were spun down and
resuspended in 100 piL DPBS. Samples were placed in a 96-well glass bottom plate
(MatTek) and PL spectra were measured in the wavelength of 1,000 - 1,350 nm. Samples
were excited for five minutes. Spectra were subtracted against background. Cells were
counted using a ViCell analyzer (Beckman Coulter, CA) and used to normalize PL
intensity measurements. Samples were measured in triplicate.
DOX conjugation onto M13-SWNT-SBP
Doxorubicin (DOX) hydrochloride was purchased from Sigma-Aldrich and EDC and
Sulfo-NHS were purchased from Thermo Scientific. .4mg of EDC and 1.1mg of sulfo-
NHS were incubated with 1013/ml M13-SWNT-SBP for 15 minutes in 3x EDC activation
buffer (.3M MES, 1.5M NaCl, pH 6.0). The EDC reaction was quenched with 20mM 2-
mercaptoethanol (Thermo Scientific). DOX was added at 50-100 pg/ml for the
conjugation reaction and the reaction was allowed to proceed for 2 hours at room
temperature in a fume hood. The conjugation was quenched with 10mM hydroxylamine
to hydrolyze unreacted NHS and regenerate original carboxyl groups. After conjugation,
the reactions was dialyzed against PBS for 2 days using dialysis membrane, MWCO of
12,000 - 14,000, (SpetraLabs.com) with frequent buffer exchange.
Cytotoxicity Assay
To evaluate cytotoxicity, M13-SWNT-SBP-DOX and M13-SWNT-SBP were incubated
with C4-2B and DU145 cells for 9 hours at 37 0 C in 50% DPBS, 50% PBS. Complexes
were removed and cells were washed with PBS and were subsequently grown for 14
hours in complete DMEM or TMEM. An MTT assay was used to quantify cell growth.
Cells were incubated with 12 mM MTT reagent for 4 hours. Cells were then washed and
incubated with SDS-HCL for another 4 hours. The reaction was mixed, and the
absorbance was read at 570 nm. Samples were measured in triplicate.
MALDI-TOF Mass Spectrometry
M13-SBP-SWNT-DOX was digested with chymotrypsin in order to understand the drug
release mechanism. Chymotrypsin was reconstituted at lmg/ml in 1mM HCl solution.
Phage was incubated in digestion buffer (5x 500mM ammonium bicarbonate, 10mM
CaCl, 500mM Tris HCl) in a iml total volume and pH was adjusted to 8.0. Cysteines
were reduced using 10mM DTT, incubated at 60 *C for 45 minutes. After cooling to
room temperature, 500mM iodoacetamide was added as an alkylating agent. This
reaction is allowed to proceed for 30 minutes and was quenched with DTT. After
alkylating and reducing the phage it was digested with chymotrypsin (lmg/ml) for 24
hours at 37 *C. Samples were stored at -80 *C until mass spectrometric analysis.
Immediately before analysis, samples were resolved using a C18 column (Thermo
Scientific).
Mass Spectrometry Data Analysis
Raw data from MALDI-TOF was bucketed into 1m/z increments by integrating spectra
intensities. As such, the data set was condensed to 2500, each at a m/z integer value
between 500 and 3000. This simplified data set was analyzed in Matlab.
Cathepsin B digestion
3 units of cathepsin B were activated at room temperature for 15 minutes in activation
buffer (15mM EDTA 30mM DTT) in 30 ul total volume. Digestion buffer (25mM
sodium acetate, 1mM EDTA, ph5.0) was pre-warmed to 37 *C. Phage and cathepsin B
were added to the buffer and incubated at 37 *C for 24 hours. Phage was precipitated by
incubation with 25% PEG-NACL on ice overnight and centrifugation at 10,000 RPM for
10 minutes.
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